External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

British Journal of Cancer

Volumn 78, Issue 11, 1998, Pages 1434-1441

  Sweep, C G J ^a   Geurts Moespot, J ^a   Grebenschikov, N ^a   De Witte, J H ^a   Heuvel, J J T M ^a   Schmitt, M ^b   Duffy, M J ^c   Janicke F ^d   Kramer, M D ^e   Foekens, J A ^f   Brunner N ^g   Brugal, G ^h   Pedersen, A N ^g   Benraad, Th J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g FINSEN LABORATORY   (Denmark)

^h UNIV GRENOBLE ALPES   (France)

Author keywords

Breast cancer; Enzyme linked immunosorbent assay; EORTC; PAI 1; Quality assessment; uPA

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION; XENOGRAFT;

EID: 7844236388     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.704     Document Type: Article

References (17)

1. Andreasen PA, Kjøller L, Christensen L and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
2. Benraad ThJ, Geurts-Moespot J, Grondahl-Hansen J, Heuvel JJTM, de Witte JH, Hoekens JA, Leake RE, Brünner N and Sweep CGJ (1996) Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-I workshop. Eur J Cancer 32A: 1371-1381
3. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
4. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas: preliminary report. Cancer 62: 531-533
5. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618
6. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105
7. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F and Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
8. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H and Klijn JGM (1995) Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 predict poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756
9. Grebenschikov N, Geurts-Moespot A, de Witte H, Heuvel J, Leake R, Sweep F and Benraad Th (1997) A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type 1 (PAI-1) in breast tumour cytosols. Int J Biol Markers 12: 6-14
10. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Dano K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
11. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
12. Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type 1 inhibitor in breast cancer. Sem Thromb Hemost 17: 303-312
13. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic markers in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
14. Mignatti P and Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195
15. Romain S, Spyratos F, Laine-Bidron C, Bouchet C, Guirou O, Martin PM, Oglobine J and Magdelenat (1995) Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-I in breast cancer tissues. Eur J Clin Chem Clin Biochem 33: 603-608
16. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F and Graeff H (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemostasis 78: 285-296
17. Spyratos F, Martin PM, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Le Doussal V, Tubiana-Hulin M and Brunet M (1992) Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272